← All science articles

· 2 min read

Defibrotide Blocks Calcium-Driven Neutrophil Activity in Lab Study

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Di Perri and colleagues, writing in Angiology in 1991, studied defibrotide, a polydeoxyribonucleotide drug already known for its effects on blood clotting and blood flow, to find out whether it also acts directly on immune cells called neutrophils. Neutrophils are white blood cells that can worsen tissue damage during periods of restricted blood flow and the reperfusion that follows.

Working with human neutrophils in the laboratory, the researchers triggered the cells with several activating compounds, including fMLP and the calcium ionophores A23187 and ionomycin. Defibrotide, added at 10 to 100 microM, reduced enzyme release, superoxide generation and chemiluminescence - all markers of neutrophil activation - in a dose-dependent way. Using a fluorescent calcium-sensing probe, the team showed defibrotide limited the rise in calcium inside the cells by blocking calcium entry from outside, a behavior similar to calcium channel-blocking drugs. Raising extracellular calcium weakened this inhibitory effect.

This was a cell-culture study, not a test in whole animals or people, so it cannot show whether this mechanism translates into clinical benefit during real ischemic injury. The authors propose the calcium-blocking action as a possible explanation for defibrotide's protective effects, but call it one piece of a larger picture.

Our reflection

This 1991 paper is part of the decades-long effort to understand how polydeoxyribonucleotide molecules interact with living cells, long before today's interest in skin and tissue applications. It documents a specific, testable mechanism - calcium regulation in immune cells - that added early mechanistic weight to this class of compounds. At Havdis, we see such foundational pharmacology as part of the long arc that today's PDRN research builds upon.

Source

Di Perri T, Pasini FL, Ceccatelli L, Pasqui AL, Capecchi PL (1991). Angiology.

Read the paper on PubMedDOI: 10.1177/000331979104201206

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.